{
    "nctId": "NCT03949634",
    "briefTitle": "Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin\uff08PLD)",
    "officialTitle": "Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin\uff08PLD\uff09\uff1aan Dynamic Randomized, Positive Control, Open, Multicenter Clinical Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Early Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 272,
    "primaryOutcomeMeasure": "cardiotoxity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1.Subjects had histopathologically confirmed early stage breast cancer with adjuvant chemotherapy treatment evidence;\n* 2.Age :18-75years old female;\n* 3.High risk of recurrence: axillary lymph node-positive, or axillary lymph node negative with at least one of the following risk factors: triple negative breast cancer, histological grade III, the maximum tumor diameter\\> 5cm, Ki 67 \u2265 50%, vascular thrombosis positive;\n* 4.ECOG score 0-1;\n* 5.Expected survival time \u2265 12 months;\n* 6.LVEF \u2265 55%;\n* 7.Normal ECG, ST segment depression in patients such as coronary angiography, confirm \\<50% stenosis or incidental premature beats are acceptable;\n* 8.Bone Marrow Function: ANC\uff1a\u22651.5\u00d7109/L\uff1b PLT\uff1a\u2265100\u00d7109/L\uff1bHb: \u226590g/L;\n* 9.Liver and renal function:Serum creatinine \u2264 normal upper limit (ULN) 1.5times; aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\u2264ULN 2.5times; total bilirubin (TBil) level:\u2264 ULN 1.5 times, or \u2264 ULN 2.5times if Gilbert's syndrome are present;\n* 10.Subjects are well-behaved, able to undergo treatment and follow-up, and voluntarily comply with this study and understood the study's research process and signed the informed consent.\n\nExclusion Criteria:\n\n* 1.New York Heart Association (NYHA) Class II or greater heart failure;\n* 2.Severe heart disease or discomfort, including but not limited to: High-risk uncontrolled arrhythmias, atrial tachycardia (heart rate\\>100/min at rest), significant ventricular arrhythmias (ventricular arrhythmias) or higher, atrioventricular block (\\[Mobitz 2\\] or third-degree atrioventricular block); Angina pectoris that needs to be treated with anti-anginal medicine; Valvular heart disease with clinical significance; Electrocardiogram shows transmural myocardial infarction; Uncontrolled high blood pressure(eg: Systolic blood pressure\\> 180 mmHg or diastolic blood pressure\\> 100 mmHg);\n* 3.Prior received neoadjuvant chemotherapy;\n* 4.Severe systemic infection or other serious disease;\n* 5.Allergies to chemotherapeutic drugs or their excipients or intolerant patients;\n* 6.Other malignant tumors have been found in the past 5 years,except for cured cervical carcinoma in situ, non melanoma of the skin;\n* 7.Childbearing age patients who are pregnant or lactation and refusing to take effective contraceptive measures during the trial;\n* 8.Received any other test drug treatment or participated in other clinical trials at the same time;\n* 9.Other conditions considered to be inappropriate to be enrolled by the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}